Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intellikine and the PKD Foundation have partnered to investigate novel, orally-available small molecule kinase inhibitors of the TORC1 and TORC2 complexes as a treatment for polycystic kidney disease (PKD).
Subscribe to our email newsletter
Initially, the PKD Foundation will help Intellikine to evaluate the drug candidates using pre-clinical models of the disease.
PKD Foundation chief scientific officer Jill Panetta said Intellikine is their first collaboration under their Drug Repurposing Program, and they are thrilled to work together to accelerate the development of their exciting TORC1/2 inhibitors as a potential treatment for patients with PKD.
Intellikine president and CEO Troy Wilson said through the Accelerating Treatments to Patients (ATP) program, not only are they able to garner financial support, but are able to engage the entire PKD community, from research and clinical experts in the field of PKD to empowered patients and their families affected by the disease.
"The ATP program allows us to broaden our research and development activities in PKD with the hope of bringing new agents to patients more quickly," Wilson said.